Mesothelioma and Asbestos

A clinical trial published in the Journal of Pain Management found that Sativex, an oral spray that contains common cannabis extracts, provides significant reduction in cancer pain in comparison to placebo or THC alone. Researchers from the United Kingdom, Belgium as well as Romania conducted the double blind, randomized, placebo-controlled trial to assess the analgesic properties of Sativex with 177 patients with intractable cancer pain.

In the study, the researchers concluded that the marijuana extracts found in Sativex are more efficacious for the treatment of cancer pain in patients who are not responding well enough to opioid analgesics. There is evidence that there is an additional synergy between THC as well as CBD that makes Sativex best at treating intractable cancer pain than THC alone.

The U.S. Food as well as Drug Administration (FDA) authorized the recruitment of patients for the earliest ever U.S. trial of studying the effects of Sativex for cancer pain in 2006. So far, 360 patients possess been recruited into the study, as well as results should be reported in spring 2010. Sativex has legal approval in Canada as well as is pending regulatory approval in both Large Britain as well as the European Union.

For the filled story, go to eNews Park Forest.